Searchable abstracts of presentations at key conferences in endocrinology

ea0046p18 | (1) | UKINETS2016

High-grade neuroendocrine tumours of the oesophagus: a single centre experience

Salih Zena , Patrao Ana , Kordatou Zoe , Papaxoinis George , Mansoor Was

Background: High-grade neuroendocrine tumours (HGNETs) of the oesophagus are extremely rare and few cases have been reported worldwide. Here we aim to understand clinical profile, treatment strategy and outcomes for oesophageal HGNETs.Methods: We report a single-centre retrospective review of 21 patients with oesophageal HGNETs treated between 2011–2016. Data on incidence, tumour location, stage at presentation, histopathology, treatment protocol an...

ea0046p21 | (1) | UKINETS2016

Efficacy of the combination of Capecitabine and Temozolamide in patients with advanced Pulmonary Carcinoid Tumors: A single institution experience

Kordatou Zoe , Papaxoinis George , McCallum Lynn , Salih Zena , Nasralla Magdy , Nonaka Daisuke , Mansoor Wasat

Background: Pulmonary carcinoids (PC) are rare neuroendocrine tumors (NETs). The course of PCs is considered to be indolent, but patients with advanced disease have low survival rates and their treatment options are limited. As PCs are under-represented in trials, therapeutic decisions are based on evidence extrapolated from other types of NETS. Capecitabine-Temozolamide (CAPTEM) has demonstrated significant efficacy in pancreatic NETs. However, its role in PCs is still unexpl...

ea0052p21 | (1) | UKINETS2017

Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence

Frizziero Melissa , Lamarca Angela , Kordatou Zoe , Barriuso Jorge , Nuttall Christina , McNamara Mairead G. , Hubner Richard A. , Mansoor Wasat , Manoharan Prakash , Valle Juan W.

Introduction: Platinum-etoposide is considered standard-of-care first-line treatment for patients diagnosed with advanced EP-PD-NECs. The optimal platinum-etoposide schedule remains undefined; carboplatin is often substituted for cisplatin, although quality data is lacking.Methods: Electronic records of patients with advanced EP-PD-NEC treated with carboplatin-etoposide (06/09-02/17) were reviewed retrospectively, with aim to provide real-life efficacy/s...